[埃尔达非替尼单药治疗fgfr3改变的晚期尿路上皮癌，此前至少有一条抗pd -1/PD-L1治疗线]。

{"title":"[埃尔达非替尼单药治疗fgfr3改变的晚期尿路上皮癌，此前至少有一条抗pd -1/PD-L1治疗线]。","authors":"Clément Grosnon, Mathieu Jamelot","doi":"10.1016/j.bulcan.2024.12.020","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 6","pages":"Pages 566-568"},"PeriodicalIF":0.8000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Erdafitinib en monothérapie dans le carcinome urothélial avancé avec altération FGFR3 après au moins une ligne de traitement avec un anti-PD-1/PD-L1\",\"authors\":\"Clément Grosnon, Mathieu Jamelot\",\"doi\":\"10.1016/j.bulcan.2024.12.020\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":9365,\"journal\":{\"name\":\"Bulletin Du Cancer\",\"volume\":\"112 6\",\"pages\":\"Pages 566-568\"},\"PeriodicalIF\":0.8000,\"publicationDate\":\"2025-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Bulletin Du Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0007455125001341\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bulletin Du Cancer","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0007455125001341","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}